Introduction
Ewing’s sarcoma (ES) is a highly malignant tumour of bone and/or soft
tissue, which is commonly observed during adolescence and young
adulthood, and exhibits a distinct propensity for aggressive
behaviour.1 It accounts for approximately 15% of all
bone malignancies and primarily affects the metaphyseal region of long
bones, representing around 80% of reported cases.2,3Furthermore, at the time of diagnosis, around 20% of patients have
metastatic spread to distant sites.4
Ewing’s sarcoma is typically found in the axial and appendicular
skeleton, but rarely occurs in the foot, particularly in the
talus.5 It has been reported that the occurrence of ES
has not been linked to hereditary or congenital syndromes, environmental
factors, or established risk factors. In approximately 90% of cases,
the neoplastic cells of Ewing’s sarcoma family tumours (ESFT) show a
characteristic translocation t(11;22)(q24;q12), while the remaining 10%
display a variant translocation, specifically
t(21;12)(22;12).6 Prognostic indicators that result in
poor outcomes include tumour size of 8 cm or larger, primary tumour
located in the pelvic region, presence of metastases, and age exceeding
15 years at the time of diagnosis.7